Congenix Adds Russian Presence to Health Decisions' Agile Clinical Network
Health Decisions announces that Moscow-based CRO Congenix has become a certified member of the Agile Clinical Network-a community of research partners with the goal of higher efficiency standards in complex global studies.
Congenix has received certification after completing "rigorous" training in Agile Clinical development techniques.
“Conducting global, multi-center trials with a network of regionally focused CROs offers many advantages over a single large CRO with international offices,” said Vladimir V. Novakovskiy, M.D., Ph.D., managing director, Clinical Operations and Regulatory Affairs, Congenix, LLP. “We look forward to bringing our extensive knowledge of Eastern Europe and Russia to the Agile Clinical Network to better assist sponsors with assessing investigators, cooperating with the local regulatory bodies, and recruiting study subjects.”
According to Dr. Novakovskiy, Eastern Europe and Russia offer sponsors high recruitment rates, an excellent selection of high-quality investigational sites, and lower cost per patient compared to Western Europe and the U.S. Other benefits include Russia’s highly centralized healthcare system and a large percentage of treatment-naïve patients.
A UK-registered CRO with offices in Moscow and Hercules, CA, USA, Congenix offers Phase I to IV services including regulatory affairs, clinical monitoring, project management, investigational site management, study supplies custom clearance, warehousing and distribution. Working within the Agile network, Congenix will have access to Health Decisions’ and other members’ high-efficiency data management systems, biostatistics expertise, medical writers, advanced data collection tools, and real-time reporting capabilities, as well as regional infrastructure around the world.
"We welcome Congenix to the Agile Clinical Network and look forward to our working together on global trials that will maximize efficiency and transparency,” said Rick Farris, Chief Operations Officer at Health Decisions. “Congenix will be a great asset to our Network as we expand its mission to deliver accurate trial results...”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
